Introduction:
Proton pump inhibitors are a class of drugs that treat many different diseases associated with the production of acid in the stomach. These drugs are an effective tool for treating disorders associated with acidity. These pharmacological agents work by blocking the glands that produce stomach acid. Gastroenterologists frequently use them as the initial treatment choice for various conditions such as esophagitis, non-erosive reflux disease, peptic ulcer disease, prevention of ulcers induced by nonsteroidal anti-inflammatory drugs, Zollinger-Ellison Syndrome, and as part of the triple therapy regimen for Helicobacter pylori infections.
How Do Proton Pump Inhibitors Work in the Human Body?
PPIs mostly function by lowering the amount of acid produced in the stomach. These medications enter the bloodstream and target the parietal cells in the stomach after being absorbed in the small intestine. PPIs obstruct the H+/K+ ATPase enzyme, also referred to as the proton pump, which is the key enzyme in these cells and the last stage in the secretion of acid into the stomach. The parietal cells' acidic secretory canaliculi are where PPIs undergo a chemical breakdown before they become active, which is interesting because PPIs are actually prodrugs. Hepatic P450 enzymes break down proton pump inhibitors (PPIs), with CYP2C19 (main enzyme). It makes sense why some people react differently to different PPIs when one understands how PPIs are metabolized.
What Are the Renal Effects of Prolonged Use of Proton Pump Inhibitors?
The various renal conditions that developed due to prolonged use of proton pump inhibitors are mentioned below:
1. Acute Interstitial Nephritis (AIN):
Acute interstitial nephritis is a kidney problem linked to a sudden decline in kidney function. It shows signs of inflammation and swelling in the renal interstitium when examined under a microscope. Acute interstitial nephritis is commonly used; acute tubulointerstitial nephritis is a more accurate description because both the renal tubules and the interstitium are affected. AIN has become a significant cause of sudden kidney failure due to allergic reactions from drugs, especially with the increased use of antibiotics and other medications that may trigger an allergic response in the interstitium.
-
The Relationship Between Chronic Kidney Disease and Proton Pump Inhibitors - To treat peptic ulcer disease and dyspepsia, proton pump inhibitors are prescribed in millions of prescriptions each year. This medication class is thought to frequently cause acute interstitial nephritis (AIN) when taken as prescribed. It happens as a result of the medication or one of its byproducts triggering an immune response. The initial case report mentions Omeprazole-induced acute adverse events. PPI-induced acute interstitial nephritis (AIN) tends to affect people in their middle or older age, consistent with those who experience symptoms of dyspepsia.
2. Chronic Kidney Disease:
CKD is a condition where the kidneys are damaged and can't clean the blood as they should. This leads to extra fluid and waste staying in the body, causing other health issues like heart disease and stroke. CKD may lead to various health issues such as anemia (resulting in a low number of red blood cells), an increased likelihood of infections, imbalances in calcium, potassium, and phosphorus levels in the blood, a decreased appetite or reduced food intake, and feelings of depression or a lower quality of life.
-
The Relationship Between Chronic Kidney Disease and Proton Pump Inhibitors - The exact reason behind the higher risk of chronic kidney disease resulting from proton pump inhibitor use is not known. Some research suggests that infections and inflammation might play a part in CKD development among PPI users. According to certain studies, inflammation and infections may contribute to the development of CKD in PPI users. Research findings indicate that PPIs may alter the microbiota in the gut. This will affect the microbial imbalance. Finally, it will increase the risk of intestinal infections. Certain types of bacteria in the gut belonging to Streptococcaceae and Enterobacteriaceae become more common in PPI users. It also plays a role in the accumulation of toxic substances from the gut, which can eventually cause CKD to worsen.
3. Renal Hypomagnesemia: This is a disorder where the blood's magnesium levels fall abnormally low; PPIs have been connected to this condition. Many physiological processes, such as the health of muscles and nerves and the preservation of a regular heartbeat, depend on magnesium. It is unknown how PPIs cause hypomagnesemia. As of right now, urinary magnesium excretion is not elevated in PPI users, excluding urinary magnesium losses as a possible mechanism. There is proof that intestinal magnesium loss or malabsorption occurs. Certain alleles of the TRPM6/TRPM7 (transient receptor potential cation channel subfamily M member 6 and 7) genes are linked to persistent magnesium losses in the urine and mild intestinal malabsorption, which may be made worse in susceptible individuals by the use of PPIs.
The Food and Drug Administration suggests that doctors think about checking magnesium levels in the blood before starting PPIs. In some situations, like long-term use (more than 1 year) or if other medications that can lower magnesium levels are being taken at the same time (such as diuretics or Digoxin).
What Are the Precautions Taken While Using Proton Pump Inhibitors?
Although there are worries about the effects of prolonged PPI use on the kidneys, it's important to remember that PPIs are generally regarded as safe when taken as directed and for brief periods of time. Patients should only take PPIs under the supervision of a healthcare provider and exercise caution when self-medicating with these medications without appropriate medical supervision.
When it is appropriate, doctors should carefully consider whether long-term PPI therapy is necessary and look into alternative treatment options. When patients are receiving prolonged PPI therapy, regular blood tests to monitor kidney function can help detect any early indications of renal impairment.
Conclusion:
Millions of patients worldwide have found relief from acid-related gastrointestinal disorders thanks to proton pump inhibitors, which have completely changed the way these disorders are treated. However, the possible effects on the kidneys from long-term PPI use highlight how important it is to prescribe carefully and keep an eye on those who take them. Patients and doctors should discuss and decide together on the use of PPIs based on individual medical needs. Patients and doctors need to communicate regularly in order to get the best treatment outcomes and minimize any side effects.
